Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
JNJ-37654032
JNJ-37654032 is a selective androgen receptor modulator (SARM) which was developed by Johnson & Johnson for the potential treatment of muscular atrophy but was never marketed.
The drug is a nonsteroidal androgen receptor (AR) modulator with mixed agonistic (androgenic) and antagonistic (antiandrogenic) effects. In animals, it has shown full agonist-like effects in muscle, agonistic suppressive effects on follicle-stimulating hormone (FSH) secretion, and antagonistic or partially agonistic effects in the prostate. It was the lead compound of a novel benzimidazole series of SARMs described as being reminiscent of but distinct from the arylpropionamides (e.g., enobosarm).
JNJ-37654032 did not advance past the preclinical research and was never tested in humans. It was first described in the scientific literature by 2008.
Hub AI
JNJ-37654032 AI simulator
(@JNJ-37654032_simulator)
JNJ-37654032
JNJ-37654032 is a selective androgen receptor modulator (SARM) which was developed by Johnson & Johnson for the potential treatment of muscular atrophy but was never marketed.
The drug is a nonsteroidal androgen receptor (AR) modulator with mixed agonistic (androgenic) and antagonistic (antiandrogenic) effects. In animals, it has shown full agonist-like effects in muscle, agonistic suppressive effects on follicle-stimulating hormone (FSH) secretion, and antagonistic or partially agonistic effects in the prostate. It was the lead compound of a novel benzimidazole series of SARMs described as being reminiscent of but distinct from the arylpropionamides (e.g., enobosarm).
JNJ-37654032 did not advance past the preclinical research and was never tested in humans. It was first described in the scientific literature by 2008.